Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Bridging Research, Policy, and Practice: Advancing Evidence-Informed Approaches for Dementia Care and Prevention: an expert review by the Health Policy Professional Interest Area from ISTAART.

Alzheimer's & dementia. Behavior & socioeconomics of aging·2026
Same author

Illuminating the molecular basis of human daylight vision.

Science (New York, N.Y.)·2026
Same author

The cost of dementia in the United States in 2026.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.

medRxiv : the preprint server for health sciences·2026
Same author

Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.

medRxiv : the preprint server for health sciences·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Keith N Fargo1, Melissa J Armstrong2, Larry J Bauer3

  • 1Lewy Body Dementia Association, Lilburn, GA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La opinión de los pacientes de una reunión externa de Desarrollo de Fármacos Centrado en el Paciente (PFDD) destacó los síntomas clave y las prioridades para los tratamientos de la demencia con cuerpos de Lewy (DCL). Las terapias futuras deben abordar el deterioro cognitivo y ofrecer alivio sintomático sin empeorar otros problemas.

Palabras clave:
Demencia con cuerpos de LewyDesarrollo de fármacosPrioridades del pacienteTratamiento de síntomasModificación de la enfermedad

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurociencia; Neurología; Farmacología

Sus antecedentes:

  • La demencia con cuerpos de Lewy (DCL) es una demencia común caracterizada por agregados de alfa-sinucleína, que causa alteraciones cognitivas, psiquiátricas y del sueño. La DCL presenta costos de atención significativos y carece de tratamientos aprobados por la FDA, lo que ha provocado un mayor interés por parte de los desarrolladores de fármacos. Las reuniones de Desarrollo de Fármacos Centrado en el Paciente (PFDD) tienen como objetivo integrar las experiencias de los pacientes en el desarrollo de fármacos.

Objetivo del estudio:

  • Capturar las experiencias vividas, las necesidades de tratamiento y las preferencias de las personas con DCL y sus cuidadores. Informar a los desarrolladores de fármacos y a las agencias reguladoras sobre las prioridades de los pacientes para futuras terapias de DCL. Guiar el desarrollo de tratamientos efectivos y centrados en el paciente para la DCL.

Principales métodos:

  • Una reunión de PFDD dirigida externamente (EL-PFDD) sobre DCL fue copatrocinada por la Lewy Body Dementia Association (LBDA) y la Alzheimer's Association (ALZ). Se solicitaron comentarios públicos sobre las experiencias vividas y los valores de tratamiento antes de la reunión. Los asistentes, incluidas personas con DCL, cuidadores y representantes de la industria/reguladores, compartieron experiencias y participaron en encuestas en vivo.

Principales resultados:

  • Los síntomas más impactantes incluyeron deterioro cognitivo, fluctuaciones, características neuropsiquiátricas y somnolencia, que varían con la progresión de la enfermedad. Las preocupaciones futuras se centraron en el deterioro cognitivo progresivo, los cambios de comportamiento y los costos de atención. Las limitaciones del tratamiento actual implican la falta de opciones aprobadas por la FDA y los efectos secundarios/ineficacia de los medicamentos fuera de etiqueta.

Conclusiones:

  • La reunión EL-PFDD recopiló con éxito información crucial de los pacientes para el desarrollo de fármacos y las consideraciones regulatorias de la DCL. Las prioridades para los tratamientos futuros incluyen el alivio sintomático, las terapias modificadoras de la enfermedad, la mejora de la accesibilidad y la minimización de los efectos secundarios. Se publicará un informe integral de 'Voz del Paciente' en el sitio web de LBDA.